DCIS - Our Science-Discovery-Development-Validation | DCISionRT

PublicationsPrelude2018-11-02T15:24:03-06:00

Wadsten, C et al. ASCO; Abstract: Risk stratification in early stage luminal breast cancer patients treated with and without RT

June 28th, 2019|

Wadsten, C et al. ASCO; Poster: Risk stratification in early stage luminal breast cancer patients treated with and without RT

June 28th, 2019|

Whitworth, PW et al. ASBS; Abstract: Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy Benefit in Patients with DCIS

May 1st, 2019|

Whitworth, PW et al. ASBS; Poster: Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy Benefit in Patients with DCIS

May 1st, 2019|

Bremer, TM et al. A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk, Clinical Cancer Research 2018, Published Online 12/01/2018

December 1st, 2018|

Wärnberg, F et al. A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS), SABCS 2017; Abstract: 851741

December 13th, 2017|

Bremer, TM et al. MBCC 2017; Poster: Utility of the DCIS Biological Risk Profile for Predicting Recurrence Risk Compared to Standard Clinicopathologic Factors

April 12th, 2017|

Bremer, TM et al. MBCC 2017; Abstract: Utility of the DCIS Biological Risk Profile for Predicting Recurrence Risk Compared to Standard Clinicopathologic Factors

April 12th, 2017|

Bremer, TM et al. SABCS 2016; Publication Number: S5-01 – AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S5-01

December 9th, 2016|

Bremer, TM et al. A multi-marker test for invasive risk post DCIS treated with BCS +/- RT, ASCO 2016; Abstract 1019

April 30th, 2016|